This article is in response to the press release of June 10, 2013 from Dynavax (NASDAQ:DVAX) regarding ongoing discussions with the FDA and the pros and cons of potential courses of action by current investors together with the author's conclusion.
Dynavax is a clinical-stage bio-pharmaceutical company with an under development product named "Heplisav" , a vaccine for the prevention of Hepatitis B. In November, 2012, the company received the FDA's advisory committee's report and in February of this year received an answer from the FDA that it agreed with the -committee. Basically, it stated that a wider study of the safety of the vaccine was required. At the same time they agreed that the vaccine was superior...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|